Novel targeted therapies and immunotherapy for advanced thyroid cancers
Abstract Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most anaplastic types, remain resistant to standard treatment options, including radioactive iodine (RAI). In addition, a...
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
BMC
2018-02-01
|
| Sarja: | Molecular Cancer |
| Linkit: | http://link.springer.com/article/10.1186/s12943-018-0786-0 |